Health News Releases

  • Today May 18
July 12, 2018 16:15
EUSA Pharma: NICE Approves the Targeted Cancer Immunotherapy, QARZIBA®▼ (dinutuximab beta) to Treat Children with High-Risk Neuroblastoma
EUSA Pharma today welcomed a decision by the National Institute for Health and Care Excellence (NICE) to recommend the use of the targeted cancer immunotherapy, QARZIBA® (dinutuximab beta) to treat ch
July 11, 2018 17:20
President Clinton to Deliver Closing Keynote Address on Eliminating Preventable Deaths in Hospitals at the 7th Annual World Patient Safety, Science & Technology Summit
For the seventh year in a row, U.S. President Bill Clinton will address healthcare leaders and deliver the closing keynote remarks at the 7th Annual World Patient Safety, Science & Technology Summit,
July 11, 2018 10:50
Takeda Receives Clearance from the United States Federal Trade Commission for the Proposed Acquisition of Shire plc
Takeda Pharmaceutical Company Limited: NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF
July 10, 2018 17:35
Boehringer Ingelheim Invests More Than €200 Million to Establish Strategic Production Center for Veterinary Public Health in France
Boehringer Ingelheim today announced an investment of more than €200 million into a new strategic production center for Veterinary Public Health. The company will establish the new site in the French
July 10, 2018 11:05
Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-Thalassemia
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from a phase III, randomized, double-blind, multi-center clinical study (BELIEVE). Luspatercept achi
July 06, 2018 14:00
Morinaga Milk Obtains Self-Affirmed GRAS Status for Its Proprietary Immunogenic Ingredient LAC-Shield™
Morinaga Milk Industry Co., Ltd., (TOKYO:2264) today announced it has attained self-affirmed GRAS (generally recognized as safe) status in the United States for LAC-Shield, a unique immunogenic ingred
AMH Infographic
July 03, 2018 18:50
New Analysis of Rekovelle® Data Further Supports Use of AMH to Personalise Fertility Treatment
Ferring Pharmaceuticals announced today a new analysis* of data from the Phase 3 ESTHER-1 trial[1] showing that natural variations in anti-Müllerian hormone (AMH) levels during and between a woman’s m
July 03, 2018 17:05
Takeda Global Headquarters Grand Opening
Takeda Pharmaceutical Company Limited, (“Takeda”) (TOKYO:4502) today held the grand opening of Takeda Global Headquarters. The building, completed in March 2018, will serve as Takeda's head office for
July 02, 2018 17:55
CHMP issues positive opinion to expand Jardiance®, Synjardy® and Glyxambi® labels to include positive effects on cardiovascular and renal outcomes
Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) announced today that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion t
July 02, 2018 17:25
New Study Investigates the Utility of Masimo ORi™ (Oxygen Reserve Index) in Providing Early Detection of Blood Oxygenation Decrease During One-Lung Ventilation
Masimo (NASDAQ: MASI) announced today the findings of a study in which researchers evaluated the ability of Masimo ORi™ (Oxygen Reserve Index) to detect declining blood oxygenation prior to standard o
July 02, 2018 10:00
Alteogen and Lynkogen Enter into an Exclusive Option Agreement to Develop Proprietary Fusion Proteins for the Treatment of NASH and Metabolic Diseases
Alteogen Inc. (KOSDAQ:196170) and Lynkogen Inc. today announced that they have entered into an exclusive option agreement for the development of Alteogen’s novel GLP-1 mimetic and Alpha-1 Antitrypsin
June 29, 2018 17:30
World Scleroderma Day 2018: Families open up about supporting a loved one with scleroderma, in new video series
Boehringer Ingelheim today reveals a new collection of unique, personal stories and portraits from family members supporting people living with scleroderma. The collection is part of the global ‘More
June 27, 2018 17:25
New patient survey reveals: For people with atrial fibrillation, reversal of their blood thinning treatment is highly important
Results from a survey in five countries among 902 people living with atrial fibrillation (AF) reinforce the importance of patient-physician discussion around the reversal of blood thinning (anticoagul
June 27, 2018 16:00
United Arab Emirates Ministry of Health & Prevention Adopts National CCHD Newborn Screening Program Using Masimo Rad-97™ Pulse CO-Oximeters® with Eve™
Masimo (NASDAQ: MASI) announced today that the United Arab Emirates (UAE) Ministry of Health & Prevention (MOHAP) is adopting a national screening protocol for critical congenital heart disease (CCHD)
June 27, 2018 14:00
22nd Century Announces New Non-GMO, Very Low Nicotine Flue-Cured and Burley Tobacco Varieties
22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction and Very Low Nicotine tobacco, announced today that the Company has exclusively
June 26, 2018 09:25
Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that both randomised controlled trials in the EASE phase III programme, investigating the use of empagliflozin in combination
June 25, 2018 10:00
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the founda
June 19, 2018 13:45
Octapharma announces approval of new Nuwiq® product strengths in Europe, increasing dosing flexibility for patients with haemophilia A
Octapharma announced today that the European Medicines Agency (EMA) has approved an extension of marketing authorisation for its human cell line-derived recombinant factor VIII (rFVIII) product, Nuwiq
June 15, 2018 13:25
Brightree Announces eReferral Integration with athenahealth
Brightree, the leading provider of cloud-based software helping post-acute care companies improve business performance and patient outcomes, announced the release of a new solution that allows home me
June 12, 2018 14:45
New Study Investigates the Utility of Masimo SedLine® Patient State Index in Monitoring Anesthesia Depth of Patients with Healthy and Cirrhotic Livers
Masimo (NASDAQ: MASI) announced today the findings of an abstract presented at Euroanaesthesia 2018 in which researchers compared Masimo Patient State Index (PSi), a processed EEG parameter provided b
June 11, 2018 10:25
Takeda Announces Term Loan Credit Agreement and Amendment to Bridge Credit Agreement in Connection with Proposed Shire Acquisition
Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) announces that it has today entered into a term loan credit agreement for an aggregate principal amount of up to 7.5 billion USD with leadi
June 08, 2018 10:55
Impossible Foods Checks in to Hong Kong Hotels
Impossible Foods is offering its award-winning, plant-based meat at three of Hong Kong’s top-ranking hotels: Hotel ICON, Grand Hyatt Hong Kong, and InterContinental Grand Stanford Hong Kong. Imposs
June 07, 2018 15:15
Sonion and Valencell Partner to Make Biometrics Universal in Hearables and Hearing Health Markets
Sonion, the global leader in micro acoustic and micro mechanical technologies and solutions for hearing instruments and specialty earphones, and Valencell, the leading innovator in wearable biometric
June 06, 2018 12:40
Nerviano Medical Sciences Announces Collaboration and License Agreement with Merck to Discover Small Molecule Inhibitors of Certain Anticancer Targets
Today Nerviano Medical Sciences, the largest pharmaceutical R&D facility in Italy and one of the leading oncology-focused, integrated discovery and development companies in Europe, announced an agreem
June 05, 2018 14:00
New ResMed-sponsored Study Shows Switching to Bilevel PAP Saves 56% of Patients from Therapy Termination
A new study reveals that shifting patients who are struggling with adherence to positive airway pressure (PAP) therapy to a more advanced bilevel device in the first 90 days of treatment is an effecti
25 per page50 per page75 per page100 per page